VA-FLIR-SYSTEMS
7.1.2020 13:02:06 CET | Business Wire | Press release
FLIR Systems, Inc. (NASDAQ: FLIR) and ANSYS (NASDAQ: ANSS) are collaborating to deliver superior hazard detection capabilities for assisted driving and autonomous vehicles (AVs) — empowering automakers to deliver unprecedented vehicle safety. Through this collaboration, FLIR will integrate a fully physics-based thermal sensor into ANSYS’ leading-edge driving simulator to model, test, and validate thermal camera designs within an ultra-realistic virtual world. The new solution will reduce original equipment manufacturers’ (OEM) development time by optimizing thermal camera placement for use with tools such as automatic emergency braking (AEB), pedestrian detection, and within future AVs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200107005299/en/
Having the ability to test in virtual environments complements the existing systems available to FLIR customers and partners, including the FLIR automotive development kit (ADK™) featuring a FLIR Boson® thermal camera, the FLIR starter thermal dataset and the regional, city-specific thermal datasets. The FLIR thermal dataset programs were created for machine learning in advanced driver assistance development (ADAS), AEB, and AV systems.
The current AV and ADAS sensors face challenges in darkness or shadows, sun glare and inclement weather such as most fog. Thermal cameras, however, can effectively detect and classify objects in these conditions. Integrating FLIR Systems’ thermal sensor into ANSYS® VRXPERIENCE® enables simulation of thousands of driving scenarios across millions of miles in mere days. Furthermore, engineers can simulate difficult-to-produce scenarios where thermal provides critical data, including detecting pedestrians in crowded, low-contrast environments.
“By adding ANSYS’ industry-leading simulation solutions to the existing suite of tools for physical testing, engineers, automakers, and automotive suppliers can improve the safety of vehicles in all types of driving conditions,” said Frank Pennisi, President of the Industrial Business Unit at FLIR Systems. “The industry can also recreate corner cases that drivers can see every day but are difficult to replicate in physical environments, paving the way for improved neural networks and the performance of safety features such as AEB.”
“FLIR Systems’ recognizes the limitations of relying solely on gathering machine learning datasets in the physical world to make automotive thermal cameras as safe and reliable as possible for automotive uses,” said Eric Bantegnie, Vice president and General Manager at ANSYS. “Now with ANSYS solutions, FLIR can further empower automakers to speed the creation and certification of assisted-driving systems with thermal cameras.”
In addition to the city-specific data sets, FLIR has more than a decade of experience in the automotive industry. FLIR has provided more than 700,000 thermal sensors as part of its night vision warning systems for a variety of carmakers, including GM, Audi and Mercedes-Benz. Also, FLIR recently announced that its thermal sensor has been selected by Veoneer, a tier-one automotive supplier, for its level-four AV production contract with a top global automaker, planned for 2021.
FLIR Systems’ thermal-enhanced demonstration car, along with other innovative FLIR products, will be on display at the FLIR booth #8528 during the 2020 Consumer Electronics Show in Las Vegas, Nevada from January 6 - 10.
For more information on FLIR Systems’ automotive solutions, please visit https://www.flir.com/safercars .
About FLIR Systems, Inc.
Founded in 1978, FLIR Systems is a world-leading industrial technology company focused on intelligent sensing solutions for defense, industrial, and commercial applications. FLIR Systems’ vision is to be “The World’s Sixth Sense," creating technologies to help professionals make more informed decisions that save lives and livelihoods. For more information, please visit www.flir.com and follow @flir.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200107005299/en/
Contact:
Media Contact: Tim McDowd (503) 498-3146 Tim.McDowd@flir.com
Investor Relations: Lasse Glassen Addo Investor Relations Phone: 424-238-6249 Email: lglassen@addoir.com
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom